[依托泊苷21方案治疗恶性淋巴瘤]

[Etoposide 21 therapy for malignant lymphoma].

作者信息

Masaoka T

机构信息

Medical Center for Cancer and Cardiovascular Disease Osaka.

出版信息

Gan To Kagaku Ryoho. 1996 Dec;23(14):1936-40.

PMID:8978801

Abstract

UNLABELLED

Oral administration of etoposide 50 mg daily for 21 days was studied in 83 patients with malignant lymphoma who were not indicated for intensive treatment. Dose escalation to 75 mg was allowed for previously untreated cases and those with body surface over 1.5 m2. The majority of patients were: median age 69, outpatient, previously treated, with clinical stage III, IV. Overall response rate was 52.5%, including 10 CR. Response rates for each background factor were: age > or = 65, 63.8%* < 65, 36.4%, PS 0, 56.5%, 1, 53.9%, 2 approximately 3, 25.0%, outpatient 65.9%, inpatient 24.0%. Clinical stage I, II, 57.1%; III, IV, 50.0%. Dosage 50 mg 49.3%; 75 mg 85.7%. Previously untreated, 81.8%; pretreated, 47.8%*(*p < 0.05).

TOXICITY

moderate side effects such as loss of appetite, nausea and leukocytopenia were observed. Those were tolerable and recovery was achieved by reduction of dose or discontinuation. Intensive treatment is the most popular therapy for malignant lymphoma, however, there are certain patients not indicated for such intensive treatment. For such patients this etoposide 21 therapy can offer a new way of palliative therapy to allow them to remain at home while maintaining a high quality of life.

摘要

未标记

对83例不适合强化治疗的恶性淋巴瘤患者进行了研究，每日口服依托泊苷50mg，共21天。对于既往未治疗的患者以及体表面积超过1.5平方米的患者，允许将剂量增至75mg。大多数患者为：年龄中位数69岁，门诊患者，既往接受过治疗，临床分期为III、IV期。总缓解率为52.5%，包括10例完全缓解（CR）。各背景因素的缓解率分别为：年龄≥65岁，63.8%；＜65岁，36.4%；体能状态（PS）0，56.5%；1，53.9%；2至3，25.0%；门诊患者，65.9%；住院患者，24.0%。临床分期I、II期，57.1%；III、IV期，50.0%。剂量50mg，49.3%；75mg，85.7%。既往未治疗，81.8%；既往接受过治疗，47.8%（p＜0.05）。